Krystal Bio granted bullish view at RBC after blockbuster projections
Reported by Seeking Alpha · seekingalpha.com · August 14, 2026
Krystal Biotech (KRYS) stock is granted an Outperform rating with a $400 price target at RBC Capital Markets citing blockbuster sales for key products. Read more here.
What the tape says
What to watch: Target Corp. (TGT) had its price target revised toward $400 — a single analyst move is a data point, not a thesis on its own.
Market reaction today: $TGT +2.69%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Seeking Alpha's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.